Efalizumab

From Ganfyd

Jump to: navigation, search
rINN: Efalizumab
Other Names
Raptiva®
Pharmacological Information
Web information on Efalizumab
NHS Evidence on Efalizumab
DrugBank on Efalizumab
Mechanism of Action
Monoclonal antibody to cell surface receptors CD11a
Relevant Clinical Literature
Pubmed on Efalizumab
RCT with Efalizumab
Systematic reviews of Efalizumab
Efalizumab in N Eng J Med, Lancet, JAMA, BMJ
Efalizumab in Cochrane Collaboration
TRIP Database on Efalizumab
Google Scholar on Efalizumab
Bandolier on Efalizumab
UK Guidance
Nice Guidance on Efalizumab

BNF-registration required
BNF for children-registration required

UK directory of medicines
UK Medicine Guide (eg pictures of capsules)
Centre for Reviews and Dissemination databases -DARE & NHS EED (evaluates reliability of research)
Prodigy Guidance on Efalizumab
Regulatory Literature
UK SPCs of medicines with marketing authorisation
EMEA search
FDA search
Other Literature
PubChem on Efalizumab
CTD (Comparative Toxicogenomics Database) link
ChemIndustry.com link
Protein Structural Information
Biological Information (GenomeNet)
Protein Knowledgebase (UniProtKB)
Please read pharmacological data limitations
Other Wikis
Medpedia on Efalizumab (Less technical, good quality control)
Wikipedia on Efalizumab (Less technical, ? quality control)

Therapeutic humanized monoclonal antibody formally used in moderate to severe chronic plaque psoriasis directed at cell surface receptor CD11a.

Withdrawn EU 19.2.09 due to 3 cases of progressive multifocal leukoencephalopathy[1] Withdrawn US 8.4.09 with no further supples from 8 June 2009.

References

  1. ↑ MHRA Efalizumab withdrawal
Retrieved from "http://www.ganfyd.org/index.php?title=Efalizumab"
Personal tools